Context

Pixium Vision develops PRIMA, a retinal implant system to help visually impaired patients regain sight via neurostimulation. The first target indication is dry age-related macular degeneration (dry AMD), a disease that affects over 150 million people worldwide and for which there is currently no clinical treatment available.

Prior to the transaction, Pixium Vision reported positive 18-month data in a clinical feasibility study of PRIMA in France, showing significant improvement of visual acuity in patients.

Based on this successful study, Pixium Vision is preparing PRIMAvera, a pivotal study set to debut at the end of 2020, which will be the basis for a request for a CE Mark and 510(k).

The Rights Issue is intended to give Pixium Vision the resources to finance the first steps of PRIMAvera throughout 2021. It will also enable Pixium Vision to complete the US feasibility study that it is conducting in parallel. This is the study in which the first patients were successfully implanted.

Pixium_website_tombstone

About Pixium

Pixium Vision is creating a world of bionic vision for those who have lost their sight, enabling them to regain visual perception and greater autonomy. Pixium Vision’s bionic vision systems are associated with a surgical intervention and a rehabilitation period.
The Prima System sub-retinal miniature photovoltaic wireless implant is in clinical testing for patients who have lost their sight due to outer retinal degeneration, initially for atrophic dry age-related macular degeneration (dry AMD).

Discover Pixium

Hervé Ronin

Investment Banking

Hervé Ronin photo

Pierre Kiecolt-Wahl

Equity Capital Markets

Pierre Kiecolt-Wahl photo

Gregoire Angleys

Investment Banking

Gregoire Angleys photo

Deal Team

Should you want to know more about this transaction, you can contact one of the team members above

Privacy Preference Center